Cleared Traditional

K863982 - VAS-CATH PERICARDIOCENTESIS CATHETER, SET & TRAY (FDA 510(k) Clearance)

Class I General & Plastic Surgery device.

K863982 · Vas-Cath of Canada , Ltd. · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1986
Decision
10d
Days
Class 1
Risk

K863982 is an FDA 510(k) clearance for the VAS-CATH PERICARDIOCENTESIS CATHETER, SET & TRAY. Classified as Catheter, Infusion (product code JCY), Class I - General Controls.

Submitted by Vas-Cath of Canada , Ltd. (Ontario, L5a 3v3, CA). The FDA issued a Cleared decision on October 24, 1986 after a review of 10 days - a notably fast clearance cycle.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4200 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Vas-Cath of Canada , Ltd. devices

Submission Details

510(k) Number K863982 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 14, 1986
Decision Date October 24, 1986
Days to Decision 10 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
104d faster than avg
Panel avg: 114d · This submission: 10d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code JCY Catheter, Infusion
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4200
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.